avantiavanti

Kempen 6 december 2021Optionality too large to ignoreGoing into the new year, Galapagos stock is in a holding patternawaiting a catalyst to unlock the negative EV value. Given ...

Kempen 6 december 2021[b]Optionality too large to ignore[/bGoing into the new year, Galapagos stock is in a holding patternawaiting a catalyst to unlock the negative EV value. Given l...

KBC 6 augustus 2021No surprises in Galapagos’ 1H21 financial update, apart from TYK2 compound GLPG3667 now also being envisioned for development in UC in the course of 2022. Given long timelines f...

UBS 5 augustus 20212Q21 Results: Cash burn guidance unchanged, clinical progress is what mattersNeutralPT €77.00...

Goldman Sachs augustus 2021Galapagos NV (GLPG.AS): 2Q21 First Take: OpEx higher, and Toledoand Tyk2 inhibitor plans expand; our initial thoughts and questionsSellPT €49,00...

Kempen 6 augustus 2021No surprises with H121 update, cash burn guidance reiteratedNeutralPT €70.00...

Barclays 5 augustus 20212Q21 first take: Focus still on business development Stock Rating/Industry View: Overweight/Positive Price Target: EUR 75.00 ...

J.P. Morgan Cazenove 6 augustus 20212Q21 Results: Pipeline timelines reiterated, guidance confirmed. Next key event is filgo EU approval in UC by YE21 ...

Op de analyst draad staan nog een paar andere updates.Morgan StanleyToledo Demonstrates POC, But Next Compound Needed For Higher Doses; TYK2 AdvancingStock Rating OverweightPric...

Pipeline Stays Alive, But More Work To DoFirst Glance | CommentJuly 14, 2021RBC Capital Markets, LLCBrian Abrahams (Analyst) (212) 858-7066Stephen Mallon (Senior Associate)Sector: ...

Raymond JamesQuick Take From TOLEDO and TYK2 Data DumpOn Wednesday post market-close, the Galapagos team dumped top-line results for theawaited studies for its TOLEDO program and TYK2 progra...

Morgan StanleyToledo Demonstrates POC, But Next Compound Needed For Higher Doses; TYK2 AdvancingStock Rating OverweightPrice Target $118.00Matthew Harrison, Connor MeehanJuly 15, 2...

Ik heb destijds een bericht gestuurd naar Galapagos over waar de 150 miljoen opt in precies betrekking op had. Kan het antwoord niet meer terugvinden, maar herinner mij dat de bewoording per compound ...

Morgan Stanley samenvatting. Hoop later op de dag full report te plaatsen op analyst draad. Bristols TYK2 Safety Is a Positive for GLPG3667Stock Rating OverweightPrice Target $...

Recommended Price Target 78,13Buy 5Sell 2Hold 14No Rating 0BAMLJason Gerberry€78.60HoldBarclaysRosie Turner€80BuyBernsteinWimal Kapadia€67HoldBryan, Garnier...

Deutsche Bank 20 april 2021PT 110 EURBiotechnology Galapagos Initiation of CoverageWorthwhile journeys of discovery carry risk: initiate with BuyAfter the pipeline setbacks of...

Rigorous new review of SIKs biology and therapeutic potential for diseaseses.Nuts and bolts of the salt-inducible kinases (SIKs)...

Barclays 14 april 2021Stock Rating OVERWEIGHTfrom Equal WeightPrice Target EUR 80.00raised 16% from EUR 69.00Re-evaluating the pipeline: u/g to OW...

Morgan Stanley 11 maart 2021Stock Rating OverweightPrice Target $117.00Matthew Harrison, Connor MeehanCatalysts Upcoming; Revising Model for Toledo and TYK2We include both...

Goldman Sachs 11 februari 2021Galapagos NV (GLPG.AS): P3 ISABELA 1/2 trials halted due to safety;lowering PT to €64/$77 as we remove ziritaxestat from our model ...

Overzicht TPs per 11 februari 2021...

Maxim Group 10 februari 2021Ziritaxestat IPF Program Discontinued – DowngradingShares to Hold...

Kempen 11 februari 2021Ziritaxestat phase III stopped before futility analysis...

Cowen 11 februari 2021GILD AND GLPG DISCONTINUE ZIRITAXESTATSISABELA PH. IIIS IN IPF...

Barclays 19 januariStock Rating EQUAL WEIGHTUnchangedPrice Target EUR 85.50lowered -32% from EUR 125.00Recalibrating to the new reality...

quote:avantiavanti schreef op 19 januari 2021 10:19:Morgan Stanley extract uit update dd 19 januari 2021En hier full report van Morgan Stanley dd 19 januari 21 waarvan gis...

Morgan Stanley extract uit update dd 19 januari 2020Galapagos NV (GLPG.O)Too Many Catalysts In 2021 To Ignore; Upgrade To OverweightGalapagos NV (GLPG.O)RatingFrom: Equal-we...

[quote alias=BigMoepf id=13006284 date=202012171651][...Achteraf gezien hadden ze misschien beter alleen de 200mg aangevraagd. Dan had de FDA alvast geen mening over de dosages moeten geven.[/qu...

Degroof Petercam 16 december (na webast)HoldPT €90Downside risk materially reduced, but patience prevails...

Stifel na de webcast Sticking To The Sidelines Given Need For Higher Spend In An Intensely Competitive Landscape; Target Price Moves To $105...

JP Morgan CazenoveNeutralPT naar 100 euro van 120...

CitiBuy/High Risk 1HPrice (15 Dec 20 16:30) €97.06Target price €148.00...

BarclaysStock Rating/Industry View: Equal Weight/PositivePrice Target: EUR 125.00...

Stifel HoldPT $135...

Kempen vanochtend Buy PT 160 euro...

RBC extract updateGILD/GLPG: Gone But Not Filg-otten, As FDA Intransigence Forces Partnership RethinkDecember 15, 2020RBC Capital Markets, LLCBrian Abrahams (Analyst...

Morgan Stanley extract updateGilead/Galapagos: Gilead Returns Filgotinib in Europe, Will Not Proceed With non-IBD Indications in USMatthew Harrison, Connor Meehan, Thomas F Lavery, J.D....

Raymond James 15 december 2020Type A Let Them Know: US FDA Did the Heisman on Filgo...

Jefferies 16 december 2020Galapagos (GLPG NA | GLPG)HOLD, €98.12 | $117.53 PT: €118.00 | $139.50Partner Gilead is discontinuing pursuit of US filgotinib approval for arthritis after meeting FD...

Credit Suisse 10 december 2020GLPG / GILD: SIK Inhibitor Mini Primer: Understanding the Mechanism Behind the Toledo Program Stock Implications[i]Note: ik heb de inhoud van dit rap...

Credit Suisse 10 december 2020GLPG / GILD: SIK Inhibitor Mini Primer: Understanding the Mechanism Behind the Toledo Program Stock Implications[i]Note: ik heb de inhoud van dit rap...

Maxim Group 1 december 2020BuyPT $170Building-Out The IPF Franchise; Positive Phase 2 Data Reported for GLPG1205...

Extract update Credit Suisse 30 november 2020Galapagos NV - Positive Topline Results from Phase 2 PINTA Trial; IPF Assets Continue to Support Evolving GLPG storyAs anticipated, Galapago...

Extract RBC Capital Markets 30 november 20GLPG US - Another IPF Drug Shows Promising Signals, Though Remains EarlyRBC Capital Markets, LLCBrian Abrahams (Analyst) (212) 858-7066 ...

Extract Bofa Securities 30 november 20PINTA (IPF): small victory with +ve Ph2a but clinical utility remains a question markMaintain Rating: UNDERPERFORMPO: 121.00 USD | Pr...

Extract update Morgan Stanley 30 november 2020Stock Rating Equal-weightPrice Target $159.00Matthew Harrison, Connor MeehanGLPG1205 leads to ~55% reduction in FVC decline: Mgt....

[i]Note: lijvig rapport dus heb ik pdf compressed, zodat het hier past. Daarmee wat rafelig her en der. Maxim Group is recent gestart Galapagos te volgen. Het rapport bevat ook veel basis info en is...

KBC Securities 10 november 2020Galapagos - First patient treated with GLPG3667Galapagos announces first dosing of a psoriasis patient in a phase Ib trial with GLPG3667. The company envi...

Stifel 27 oktober 2020[i]Our target price for GLPG shares is $138. This is based on a probability-weighted, risk-adjusted NPV analysis. We assign $34, $2, $1, $5for filgotinib, GLPG1690, Other r...

UBS 27 oktober 202012-month rating Neutral12m price target €125.00Healing the SIK? Toledo target reveal does not change the investment case...